The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and without truncating APC-mutations, as well as in an isogenic cell line pair reporting on the status of APC- dependent selectivity. A number of very potent and selective compounds were identified, including compounds with good metabolic stability and PK properties. The small molecules reported herein thus represent a first-in-class genotype-selective series that specifically target ape mutations present in the vast majority of CRC patients, and therefore serves as a translational platform towards a potential targeted therapy for colon cancer.
本披露报告了对大量截断APC-选择性
抑制剂(TASIN)化合物的广泛药物
化学评估。这些化合物针对一系列结肠癌
细胞系进行了活性评估,包括具有截断APC突变和不具有截断APC突变的
细胞系,以及在报告APC依赖性选择性状况的同源
细胞系对。鉴定了一些非常有效和选择性的化合物,包括具有良好代谢稳定性和药代动力学性质的化合物。因此,本文报道的小分子代表了一种首创的
基因型选择性系列,专门针对存在于绝大多数结直肠癌患者中的猿类突变,因此可作为一个转化平台,朝着结肠癌的潜在靶向治疗迈进。